GWM
CORT icon

Gilpin Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Gilpin Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-16
Closed -$1.39K – 1436
2026
Q2 		$1.39K Buy
16
+8
+100% +$483 ﹤0.01% 473
2026
Q1 		$323 Buy
8
+1
+14% +$37 ﹤0.01% 747
2025
Q4 		$244 Buy
+7
New +$550 ﹤0.01% 605

Other funds holding CORT

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
RA
Riversedge Advisors Wilmington, Delaware $813M AUM 18.09% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

Gilpin Wealth Management's CORT Position: Q3 2026 in Review

Gilpin Wealth Management sold out of Corcept Therapeutics (CORT) in Q3 2026, closing a stake of 16 shares — an estimated $1.39K sold.

Gilpin Wealth Management first reported a position in CORT in Q4 2025 and held it in 3 quarters. The position peaked at $1.39K in Q2 2026. 12 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Gilpin Wealth Management reported no remaining Corcept Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Gilpin Wealth Management sold 16 Corcept Therapeutics shares in Q3 2026, an estimated $1.39K.
  • Gilpin Wealth Management first reported a position in Corcept Therapeutics in Q4 2025 and held it in 3 quarters.
  • Gilpin Wealth Management's Corcept Therapeutics position peaked at $1.39K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.